Silicone oil for post-phaco endophthalmitis: a small RCT
In 40 severe cases, silicone-oil tamponade after vitrectomy reduced recurrent infection but did not significantly improve 12-week vision.
doi: 10.4103/IJO.IJO_3296_25Retina
Macular disease and diabetic retinopathy
DME with good vision: are immediate injections always necessary?
Protocol V compared aflibercept, laser and observation for centre-involved diabetic macular oedema with good visual acuity. At two years, immediate injections did not reduce vision loss significantly.
doi: 10.1001/jama.2019.5790AREDS2 at ten years: lutein and zeaxanthin instead of beta carotene
Long-term AREDS2 follow-up supported replacing beta carotene with lutein and zeaxanthin. The revised formula retained benefit for people at risk of late AMD without increasing lung-cancer risk.
doi: 10.1001/jamaophthalmol.2022.1640Faricimab for neovascular AMD: dosing intervals up to 16 weeks
Two phase 3 trials compared faricimab with aflibercept in neovascular AMD. Faricimab produced comparable visual-acuity outcomes and allowed longer injection intervals for some patients.
doi: 10.1016/S0140-6736(22)00010-1Autonomous AI increased diabetic eye-screening completion in young patients
In the ACCESS trial, autonomous AI eye examinations were performed within a diabetes clinic. This pathway increased screening completion and follow-up compared with a conventional referral.
doi: 10.1038/s41467-023-44676-zDepression and anxiety with irreversible vision loss
A meta-analysis estimated depression and anxiety across AMD, diabetic retinopathy, glaucoma and other causes of vision loss.
doi: 10.1177/00912174251382653Ranibizumab versus laser for diabetic macular oedema
A meta-analysis compared intravitreal ranibizumab with laser photocoagulation for diabetic macular oedema.
doi: 10.3389/fendo.2025.1608456Age-related choroidal atrophy and its distinction from AMD
The review organised multimodal-imaging features of age-related choroidal atrophy.
doi: 10.1016/j.survophthal.2025.12.005Cost effectiveness of anti-VEGF treatment for wet AMD
A systematic review compared economic models for drugs used in neovascular AMD.
doi: 10.1016/j.vhri.2025.101542Aflibercept biosimilars for retinal disease
A meta-analysis compared aflibercept biosimilars with reference aflibercept in neovascular AMD and diabetic macular oedema.
doi: 10.1016/j.survophthal.2025.11.007